Program 2103

Program 2103 is a preclinical-stage small molecule inhibitor of Kinesin Family Member 18A (KIF18A) being developed by Apeiron Therapeutics. KIF18A is a mitotic kinesin motor protein that plays a critical role in chromosome alignment during cell division. By inhibiting the ATPase activity of KIF18A, Program 2103 induces mitotic defects, cell cycle arrest, and apoptosis specifically in cancer cells characterized by high chromosomal instability (CIN), a hallmark of many aggressive cancers. This mechanism allows for the selective targeting of CIN-positive tumor cells while sparing normal cells. The program is currently in the IND-enabling phase, with research demonstrating anti-tumor activity in CIN-positive xenograft models.

Other names

KIF18A inhibitor (Apeiron)